UNSPSC 51172483: Elosulfase alfa

Elosulfase alfa is a drug for the treatment of Morquio syndrome which is caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Elosulfase alfa is a synthetic version of this enzyme.

UNSPSC 51172483 Elosulfase alfa, a Commodity code, shows little relevant recent state and local procurement activity. The code nominally represents a single pharmaceutical product — elosulfase alfa, an enzyme replacement therapy used to treat mucopolysaccharidosis IVA (Morquio syndrome). However, the recent-opportunities block contains no solicitations for this specific drug. One opportunity tagged under this code is an Invitation to Quote from Seminole County, Florida (IFB60459723LAS, due July 26, 2023) for naloxone and safe drug deactivation systems — products unrelated to elosulfase alfa and likely misclassified. The remaining records are vendor networking events, trade shows, county purchasing forums, and a multi-state cooperative for generic pharmaceuticals and OTC products, none of which solicit elosulfase alfa procurement. The mismatch between the code's specificity and the actual opportunities suggests either sparse genuine activity or systematic miscoding in the state and local procurement system.

Firms should verify whether elosulfase alfa qualifies for coverage under broader pharmaceutical-supply codes or multi-state cooperative contracts before pursuing this code directly. If state and local governments require this specialty enzyme replacement therapy, procurement likely flows through existing healthcare-system supply agreements, Medicaid managed-care contracts, or specialized pharmaceutical-distribution networks rather than open competitive solicitations tagged to a single-drug Commodity code. Monitor the code for future activity, but do not expect standalone elosulfase alfa opportunities to appear with frequency in state and local notice streams.